-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Evolving Standards of Care
-
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption.
-
Overcoming Resistance Remains a Challenge in Targeting KRAS
Dana-Farber’s Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space.
-
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?
Drs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment.
-
The Elephant in the Room: Addressing Oncology’s Carbon Footprint
From travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy.
-
Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History
Lynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community.
-
Foritinib Gains Momentum in China for ALK-positive NSCLC
China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial.
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution.
-
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.
-
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case.
-
Picking Up the Pieces: The Impact of the Western US Wildfires on Cancer Care
Dr. Karen Reckamp discusses the challenges that both patients and oncologists in the Los Angeles area experienced during the devastating fires.